• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc. (Amendment)

    2/14/24 4:00:25 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BOLT alert in real time by email
    SC 13G/A 1 z111241sc13ga1.htm AMENDMENT NO.1

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

     

    SCHEDULE 13G/A

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Bolt Biotherapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

     

     

    097702104

    (CUSIP Number)

     

     

     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 8 Pages 
     

     

    CUSIP No. 097702104

     

    13G/A Page 2 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2

    Check the Appropriate Box if a Member of a Group*

    (a) ¨
    (
    b) x
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    3,652,244

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

      8

    Shared Dispositive Power

     

    3,652,244

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    3,652,244

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.6%

    12

    type of reporting person

     

    pN

     

     Page 2 of 8 Pages 
     

     

    CUSIP No. 097702104

     

    13G/A Page 3 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2

    Check the Appropriate Box if a Member of a Group*

     

    (a) ¨
    (
    b) x
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    3,652,244

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

      8

    Shared Dispositive Power

     

    3,652,244

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    3,652,244

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.6%

    12

    type of reporting person

     

    OO

     

     Page 3 of 8 Pages 
     

     

    CUSIP No. 097702104

     

    13G/A Page 4 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2

    Check the Appropriate Box if a Member of a Group*

     

    (a) ¨
    (
    b) x
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    united states

     

     

    Number of

    5

    Sole Voting Power

     

    0

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    3,652,244

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

      8

    Shared Dispositive Power

     

    3,652,244

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    3,652,244

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    9.6%

    12

    type of reporting person

     

    IN

     

     Page 4 of 8 Pages 
     

     

    Item 1(a).Name of Issuer:

     

    Bolt Biotherapeutics, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    900 Chesapeake Drive, Redwood City, CA 94063

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.00001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 097702104

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 3,652,244 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 3,652,244 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 3,652,244 shares of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 5 of 8 Pages 
     

     

    The percentages used herein are based on 37,965,870 shares of Common Stock outstanding as of November 2, 2023, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on November 9, 2023.

     

    (b)Percent of Class:

     

    Tang Capital Partners 9.6%
    Tang Capital Management 9.6%
    Kevin Tang 9.6%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Partners 3,652,244 shares
    Tang Capital Management 3,652,244 shares
    Kevin Tang 3,652,244 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 3,652,244 shares
    Tang Capital Management 3,652,244 shares
    Kevin Tang 3,652,244 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

     Page 6 of 8 Pages 
     

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 Pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 14, 2024  

     

     

    TANG CAPITAL PARTNERS, LP

     

    By: Tang Capital Management, LLC, its General Partner

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    TANG CAPITAL MANAGEMENT, LLC

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8 Pages

     

     

     

    Get the next $BOLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BOLT

    DatePrice TargetRatingAnalyst
    1/6/2022$45.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    1/6/2022Overweight → Equal-Weight
    Morgan Stanley
    11/10/2021$35.00 → $33.00Outperform
    SVB Leerink
    8/16/2021$34.00 → $35.00Outperform
    SVB Leerink
    More analyst ratings

    $BOLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

      Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will host a key opinion leader (KOL) conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and investigator on the Phase 1 dose-escalation clinical study of BDC-3042, on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET. Dr. Dumbrava will discuss the results from the Phase 1 dose-escalat

      5/8/25 8:00:00 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

      CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced preclinical results from its next-generation Boltbody™ ISACs targeting CEACAM5 and PD-L1 at the American Association for Cancer Research (AACR) Annual Meeting. "We are encouraged by these early results from our next-generation Boltbody™ ISACs targeting CEA a

      4/30/25 4:05:00 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

      BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines BDC-3042 showed signs of anti-tumor activity, including an unconfirmed partial response, stable disease ≥ 12 weeks in 3/3 non-small cell lung cancer patients and in 2/3 patients at the highest dose Bolt is running a partnering process to advance development of BDC-3042 REDWOOD CITY, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treat

      4/25/25 1:00:00 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Senior VP, Finance and PAO Nemec Sarah bought $2,835 worth of shares (5,000 units at $0.57), decreasing direct ownership by 2% to 13,863 units (SEC Form 4)

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 8:40:30 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO and CFO Quinn William P. bought $2,835 worth of shares (5,000 units at $0.57) (SEC Form 4)

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 8:35:34 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quinn William P. bought $11,241 worth of shares (11,829 units at $0.95), increasing direct ownership by 48% to 36,272 units (SEC Form 4)

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      12/13/23 1:40:19 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Bolt Biotherapeutics Inc.

      DEF 14A - Bolt Biotherapeutics, Inc. (0001641281) (Filer)

      4/25/25 3:48:22 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)

      4/16/25 5:22:57 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Bolt Biotherapeutics Inc.

      PRE 14A - Bolt Biotherapeutics, Inc. (0001641281) (Filer)

      4/15/25 7:12:43 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bolt Biotherapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Bolt Biotherapeutics from Overweight to Equal-Weight and set a new price target of $11.00 from $45.00 previously

      1/6/22 9:46:37 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics downgraded by Morgan Stanley

      Morgan Stanley downgraded Bolt Biotherapeutics from Overweight to Equal-Weight

      1/6/22 7:59:47 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Bolt Biotherapeutics with a new price target

      SVB Leerink reiterated coverage of Bolt Biotherapeutics with a rating of Outperform and set a new price target of $33.00 from $35.00 previously

      11/10/21 6:28:31 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Leadership Updates

    Live Leadership Updates

    See more
    • Bolt Biotherapeutics Announces Changes to its Board of Directors

      REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O'Callaghan, CEO of Deep Genomics, will be assuming the role of Chair. "Ja

      9/4/24 4:05:00 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira Appoints Frank D. Lee as Chief Executive Officer

      -- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the "Board") has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. As previously announced in September 2023, David Stack will retire from his r

      12/21/23 7:30:00 AM ET
      $BOLT
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

      REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022. "Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience," said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics. "As we continue to advance our immuno-oncology pipeline programs in the clinic, Laura brings important strategic perspective from leading and executing more than 50 transact

      12/14/22 4:43:15 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BOLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc.

      SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

      11/14/24 4:19:06 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc. (Amendment)

      SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

      2/14/24 4:57:08 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc. (Amendment)

      SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

      2/14/24 4:00:25 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Dupont Jakob

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 9:28:46 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Yonehiro Grant

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 8:41:01 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Senior VP, Finance and PAO Nemec Sarah bought $2,835 worth of shares (5,000 units at $0.57), decreasing direct ownership by 2% to 13,863 units (SEC Form 4)

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 8:40:30 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Financials

    Live finance-specific insights

    See more
    • Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

      Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will host a key opinion leader (KOL) conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and investigator on the Phase 1 dose-escalation clinical study of BDC-3042, on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET. Dr. Dumbrava will discuss the results from the Phase 1 dose-escalat

      5/8/25 8:00:00 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

      Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Senior Vice President of Clinical Development to oversee all clinical activities; Edith Perez moving to an advisory roleCash balance of $112.8 million now expected to fund the Company into second half 2026, including generation of clinic

      5/14/24 4:05:00 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021

      Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dose-escalation study of BDC-1001 with Opdivo® on target to initiate by year end 2021 Live conference call and webcast today at 8:00 a.m. ET/5:00 a.m. PT REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the presentation of interim clinical data from the company's ongoing Phase 1/2 study of BDC-1001, the company's lead immune-stimulat

      12/6/21 6:00:00 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care